Nathan Uy, MD
Radiation Oncology · Tulsa, OKNPI 1437148954
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.4%), travel and lodging and education — rather than concentrated in one kind of arrangement. 53 manufacturers reported payments, led by Elekta, Inc. at 42.0% of the total. Reporting peaked in 2023 at $1,937 and has fallen 63.7% since, to $704 in 2025.
Across 120 payments — averaging $42.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Elekta, Inc.$2K
- Elekta LTD$712
- Novartis$241
- AstraZeneca$209
- Daiichi Sankyo Inc.$120
- Genentech USA, Inc.$99
- plus $2K from 47 others
What the payments were for
- Travel & lodging$2,03940%
- Food & beverage$2,95958%
- Education$721%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELEKTA MEDICAL LINEAR ACCELERATOR$3,541
- Clarity$565
- ELEKTA UNITY$193
How this compares
$5,070 in reported general payments places this provider in the 85th percentile of 43 radiation oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 29 | $1,164 |
| Gabapentin | 12 | $752 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 49 | $718 |
| Tamsulosin Hcl | 22 | $417 |
| Silver Sulfadiazine | 18 | $232 |
| Nystatin | 13 | $170 |
| SsdSilver Sulfadiazine | 12 | $106 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Tulsa
- Diane HeatonTulsa$36K
- Mykhanh NguyenTulsa$15K
- Charles StewartTulsa$3K
- Terry StylesTulsa$642
- Frederick WillisonTulsa$414
- Stephen SackTulsa$373
- Ralph JensenTulsa$67
- William GoadTulsa$48
- Jerry JaboinOklahoma City$14K
- Walter WattsMuskogee$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.